Canaccord raised the firm’s price target on Boston Scientific (BSX) to $132 from $131 and keeps a Buy rating on the shares. The firm attended its investor day where they outlined its forward growth strategies and over the 2026-2028 it expects to outpace market growth in the segments it serves while also continuing to improve operating margins.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Strong Growth Potential and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Promising Growth Trajectory: A Buy Rating Backed by Strong Financial Targets and Key Franchises
- Boston Scientific’s Promising Growth Trajectory: Buy Rating Supported by Innovative Products and Strategic Expansion
- Strong Buy Rating for Boston Scientific: Promising Growth and Profitability Outlook
- Boston Scientific: Strong Growth Prospects and Strategic Initiatives Drive Buy Rating